Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119715 | 0.85 | MEN1 (0.57) | MEN1KMT2AHTTAURKAHSP90AA1 | |
| SCHEMBL6796612 | 0.80 | IKBKB (0.47) | MEN1KMT2AHTTPRKACAMAPT | |
| SCHEMBL667593 | 0.79 | AURKA (0.57) | MEN1KMT2AHTTASIC3AURKA | |
| SCHEMBL2717081 | 0.78 | MEN1 (0.62) | MEN1KMT2AHTTMAOBHSP90AA1 | |
| SCHEMBL6797231 | 0.78 | ABCG2 (0.53) | MEN1KMT2AHTTSMN1; SMN2MAPT | |
| SCHEMBL22347307 | 0.75 | MEN1 (0.59) | MEN1KMT2AHTTAURKAPRKACA | |
| SCHEMBL28458368 | 0.74 | MAOB (0.63) | MEN1KMT2AMAOBHSP90AA1POLB | |
| SCHEMBL27116353 | 0.74 | PIK3CA (0.51) | MEN1KMT2AHTTHPGDGLA | |
| SCHEMBL31571660 | 0.72 | MAPK1 (0.46) | MEN1KMT2AMAOBASIC3HPGD | |
| SCHEMBL30679410 | 0.72 | MAOB (0.56) | MEN1KMT2AMAOBASIC3HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | MEN1 2703/4885KMT2A 968/4885HTT 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.